Cargando…

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma

The cancer/testis antigens (CTAs), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen gene (MAGE)-A4 are normally restricted to male germ cells but are aberrantly expressed in several cancers. Considering the limited information regarding their significance in osteosarcoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Hashimoto, Kazuhiko, Nishimura, Shunji, Ito, Tomohiko, Oka, Naohiro, Kakinoki, Ryosuke, Akagi, Masao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251608/
https://www.ncbi.nlm.nih.gov/pubmed/35736245
http://dx.doi.org/10.4081/ejh.2022.3377
_version_ 1784740071219396608
author Hashimoto, Kazuhiko
Nishimura, Shunji
Ito, Tomohiko
Oka, Naohiro
Kakinoki, Ryosuke
Akagi, Masao
author_facet Hashimoto, Kazuhiko
Nishimura, Shunji
Ito, Tomohiko
Oka, Naohiro
Kakinoki, Ryosuke
Akagi, Masao
author_sort Hashimoto, Kazuhiko
collection PubMed
description The cancer/testis antigens (CTAs), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen gene (MAGE)-A4 are normally restricted to male germ cells but are aberrantly expressed in several cancers. Considering the limited information regarding their significance in osteosarcoma (OS), the purpose of this study was to determine the clinical significance of NY-ESO-1 and MAGE-A4 expression in OS. Nine patients with OS treated at Kindai University Hospital were included in the study. The median age was 27 years, and median follow-up period was 40 months. The specimens obtained at the time of biopsy were used to perform immunostaining for NY-ESO, MAGE-A4, p53, and Ki-67. The positive cell rates and positive case rates of NY-ESO, MAGE-A4, p53, and Ki-67 were calculated. The correlation between the positive cell rate of immunohistochemical markers was also calculated. The correlation between the positive cell rate of NY-ESO-1 or MAGE-A4 and tumor size or maximum standardized uptake (SUV-max) was also determined. The positive cell rates of NY-ESO-1 or MAGE-A4 in continuous disease-free (CDF) cases were also compared with those in alive with disease (AWD) or dead of disease (DOD) cases. The average positive cell rates of NY-ESO, MAGEA4, p53, and Ki-67 were 71.7%, 85.1%, 16.2%, and 14.7%, and their positive case rates were 33.3%, 100%, 44.4%, and 100%, respectively. The positivity rates of NY-ESO-1 and p53 were strongly correlated, whereas those of NY-ESO-1 and Ki-67 were moderately correlated. The MAGE-A4 and p53 positivity rates and the MAGE-A4 and Ki-67 positive cell rates were both strongly correlated. The NY-ESO-1 and MAGE-A4 positivity rates were moderately correlated. The positive correlation between the NY-ESO-1 positive cell rate and tumor size was medium, and that between the MAGE-A4 positivity rate and SUV-max was very strong. There was no significant difference in the positive cell rates of NY-ESO-1 or MAGE-A4 between CDF cases and AWD or DOD cases. Overall, our results suggest that NY-ESO-1 and MAGE-A4 may be involved in the aggressiveness of OS.
format Online
Article
Text
id pubmed-9251608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-92516082022-07-05 Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma Hashimoto, Kazuhiko Nishimura, Shunji Ito, Tomohiko Oka, Naohiro Kakinoki, Ryosuke Akagi, Masao Eur J Histochem Article The cancer/testis antigens (CTAs), New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and melanoma antigen gene (MAGE)-A4 are normally restricted to male germ cells but are aberrantly expressed in several cancers. Considering the limited information regarding their significance in osteosarcoma (OS), the purpose of this study was to determine the clinical significance of NY-ESO-1 and MAGE-A4 expression in OS. Nine patients with OS treated at Kindai University Hospital were included in the study. The median age was 27 years, and median follow-up period was 40 months. The specimens obtained at the time of biopsy were used to perform immunostaining for NY-ESO, MAGE-A4, p53, and Ki-67. The positive cell rates and positive case rates of NY-ESO, MAGE-A4, p53, and Ki-67 were calculated. The correlation between the positive cell rate of immunohistochemical markers was also calculated. The correlation between the positive cell rate of NY-ESO-1 or MAGE-A4 and tumor size or maximum standardized uptake (SUV-max) was also determined. The positive cell rates of NY-ESO-1 or MAGE-A4 in continuous disease-free (CDF) cases were also compared with those in alive with disease (AWD) or dead of disease (DOD) cases. The average positive cell rates of NY-ESO, MAGEA4, p53, and Ki-67 were 71.7%, 85.1%, 16.2%, and 14.7%, and their positive case rates were 33.3%, 100%, 44.4%, and 100%, respectively. The positivity rates of NY-ESO-1 and p53 were strongly correlated, whereas those of NY-ESO-1 and Ki-67 were moderately correlated. The MAGE-A4 and p53 positivity rates and the MAGE-A4 and Ki-67 positive cell rates were both strongly correlated. The NY-ESO-1 and MAGE-A4 positivity rates were moderately correlated. The positive correlation between the NY-ESO-1 positive cell rate and tumor size was medium, and that between the MAGE-A4 positivity rate and SUV-max was very strong. There was no significant difference in the positive cell rates of NY-ESO-1 or MAGE-A4 between CDF cases and AWD or DOD cases. Overall, our results suggest that NY-ESO-1 and MAGE-A4 may be involved in the aggressiveness of OS. PAGEPress Publications, Pavia, Italy 2022-06-23 /pmc/articles/PMC9251608/ /pubmed/35736245 http://dx.doi.org/10.4081/ejh.2022.3377 Text en ©Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Article
Hashimoto, Kazuhiko
Nishimura, Shunji
Ito, Tomohiko
Oka, Naohiro
Kakinoki, Ryosuke
Akagi, Masao
Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
title Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
title_full Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
title_fullStr Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
title_full_unstemmed Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
title_short Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
title_sort clinicopathological assessment of cancer/testis antigens ny-eso-1 and mage-a4 in osteosarcoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251608/
https://www.ncbi.nlm.nih.gov/pubmed/35736245
http://dx.doi.org/10.4081/ejh.2022.3377
work_keys_str_mv AT hashimotokazuhiko clinicopathologicalassessmentofcancertestisantigensnyeso1andmagea4inosteosarcoma
AT nishimurashunji clinicopathologicalassessmentofcancertestisantigensnyeso1andmagea4inosteosarcoma
AT itotomohiko clinicopathologicalassessmentofcancertestisantigensnyeso1andmagea4inosteosarcoma
AT okanaohiro clinicopathologicalassessmentofcancertestisantigensnyeso1andmagea4inosteosarcoma
AT kakinokiryosuke clinicopathologicalassessmentofcancertestisantigensnyeso1andmagea4inosteosarcoma
AT akagimasao clinicopathologicalassessmentofcancertestisantigensnyeso1andmagea4inosteosarcoma